Loading clinical trials...

Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5 | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5

Methyphendidate in the Treatment of Cocaine Dependent Patients With Adult ADHD

NCT00015223•National Institute on Drug Abuse (NIDA)

View on ClinicalTrials.gov

Summary

The purpose of this study is the use of Methylphenidate in the treatment of cocaine dependence and Attention Deficit Hyperactivity Disorder (ADHD) comorbidity.

Detailed Description

The objective of this study is to determine the safety and efficacy of methylphenidate in a population of patients who are cocaine dependent and suffer from attention deficit hyperactivity disorder.

Eligibility

Age

21 - 50 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cocaine-dependent. Meets the DSM-IV criteria for ADHD. Actively using cocaine within the past 30 days of screening.

Exclusion Criteria

•Symptoms of AIDS. Significant medical disorder. DSM-IV criteria for any substance other than cocaine, alcohol, nicotine, marijuana, caffeine. Requires detoxification from ETOH or benzos. History of seizures.

Locations (1)

Cincinnati MDRU

Cincinnati, Ohio, United States

Key Dates

Start Date

June 1, 1997

Primary Completion Date

July 1, 1999

Completion Date

August 1, 1999

Last Updated

January 16, 2017

Conditions

Cocaine-Related DisordersSubstance-Related Disorders

Interventions

Methylphenidate

DRUG

SMART-r: Substance Monitoring and Active Relapse Tracking Repository

NCT06676059

AlcoholismSubstance-Related Disorders

View study

RECRUITING

Alcohol, Psychoactive Drugs, Analgesics and Evaluation in Penetrating Abdominal Trauma

NCT07330349

Abdominal InjuriesAlcohol Intoxication+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5

Inclusion Criteria

Exclusion Criteria

SMART-r: Substance Monitoring and Active Relapse Tracking Repository

Alcohol, Psychoactive Drugs, Analgesics and Evaluation in Penetrating Abdominal Trauma

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

GLP-1R Agonist Treatment for Opioid Use Disorder

Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder